Dr Woodie Lynn Mason, MD in Madison, MS - Urology

Dr Woodie Lynn Mason, MD is a Urology physician based in Madison, Mississippi. Dr Woodie Lynn Mason is licensed to practice in Mississippi (license number 05814) and his current practice location is 115 Wildwood Dr, Madison, Mississippi. He can be reached at his office (for appointments etc.) via phone at (601) 898-0898.

NPI number for Dr Woodie Lynn Mason is 1619290400 and his current mailing address is 115 Wildwood Dr, Madison, Mississippi. He does not participate in medicare program and thus does not accept medicare assignments. His NPI Number is 1619290400.

Contact Information

	Dr Woodie Lynn Mason, MD
	115 Wildwood Dr, Madison, MS 39110-7045
	(601) 898-0898
	(601) 898-0898

Physician's Profile

Full Name	Dr Woodie Lynn Mason
Gender	Male
Speciality	Urology
Location	115 Wildwood Dr, Madison, Mississippi
Accepts Medicare Assignments	Does not participate in Medicare Program. He may not accept medicare assignment.

NPI Data:

NPI Number: 1619290400
Provider Enumeration Date: 03/08/2010
Last Update Date: 03/08/2010

Medical Identifiers

Medical identifiers for Dr Woodie Lynn Mason such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1619290400	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
208800000X	Urology	05814 (Mississippi)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Dr Woodie Lynn Mason is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Dr Woodie Lynn Mason, MD 115 Wildwood Dr, Madison, MS 39110-7045 Ph: (601) 898-0898	Dr Woodie Lynn Mason, MD 115 Wildwood Dr, Madison, MS 39110-7045 Ph: (601) 898-0898

News Archive

Investigational drug offers hope of relief for celiac disease patients exposed to gluten

An investigational new drug offers hope of relief for celiac disease patients who are inadvertently exposed to gluten while on a gluten-free diet.

New scientific article shows that Patrys' PAT-SC1 safe, well-tolerated in gastric cancer patients

Patrys Limited, a clinical stage biotechnology company is pleased to announce the publication of a new scientific article regarding its product PAT-SC1 in the Oncology Reports journal. The article is currently available online and will be included in a future print edition of the journal.

Study: Depression, behavioral changes may occur in Alzheimer's disease before memory declines

Depression and behavioral changes may occur before memory declines in people who will go on to develop Alzheimer's disease, according to new research at Washington University School of Medicine in St. Louis.

Study reveals impact of genetic make-up on response to oral antiplatelet treatment ticagrelor

A new genetic substudy of PLATO showed that the effects on a combined primary endpoint of cardiovascular death, myocardial infarction, or stroke seen in Acute Coronary Syndromes patients who received the investigational oral antiplatelet treatment, ticagrelor (BRILINTA), were maintained, whether or not they had the genetic variability that has been previously shown to affect a patient's response to clopidogrel.

Dr Woodie Lynn Mason, MD - Urology in Madison, MS